We guide induced pluripotent stem cells (iPSCs) to self-organize into a beating, hollow, spherical chamber, called a Cardioid, mimicking human heart development and physiology.

Our self-organizing Cardioids replicate the native architecture of key cardiac cell types while maintaining a consistent, physiologically relevant beating pattern, providing a powerful model for cardiac diseases.

Our Cardioids enable self-organized heart chamber formation with precise control over cellular composition, making them an ideal platform for accurate disease modeling and targeted drug discovery.

Our proprietary Cardioid technology allows us to develop customized models for heart diseases such as myocardial fibrosis, drug-induced and genetic cardiomyopathies empowering advanced, disease-relevant drug testing and discovery.

Our comprehensive assay suite leverages the unique structure and function of our cardiac chamber models, enabling precise control and characterization of heart disease phenotypes at structural, functional, and molecular levels.

It delivers deep, clinically relevant insights that go beyond the capabilities of conventional models accelerating and de-risking cardiac drug discovery.

By integrating our highly predictive cardiac model with specialized assays at a fully automated, industry-standard 384-well format, we've built a robust, scalable, and cost-effective TechBio platform designed to transform cardiac drug discovery.

• Cardioid Failure rate: < 3%
• Structural and functional variability: 6 - 14%
• Automated data analysis pipeline
• Scalable: Up to 50,000 Cardioids per month

Our proprietary human organoid biology, advanced automation, and AI-powered analytics together form the foundation of a next-generation platform for transformative cardiac drug discovery.